The psoriasis treatment market would grow at a CAGR of 8.16% over the predicted time frame. The market is expected to increase in value from US$ 27.36 Bn in 2022 to US$ 51.24 Bn in 2030.
The on psoriasis treatment Market, which provides a business strategy, research & development activities, concise outline of the market valuation, valuable insights pertaining to market share, size, supply chain analysis, competitive landscape and regional proliferation of this industry.
Download Free Sample@ https://www.precedenceresearch.com/sample/2034
Report Scope of the Psoriasis Treatment Market
| Report Coverage | Details |
| Market Size in 2022 | USD 27.36 Billion |
| Market Size by 2030 | USD 51.24 Billion |
| Growth Rate from 2022 to 2030 | CAGR of 8.16% |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segments Covered | Drug Class, Treatment Type, Type, Route of Administration, Distribution Channel, Geography |
A recent report provides crucial insights along with application based and forecast information in the Global Psoriasis treatment Market. The report provides a comprehensive analysis of key factors that are expected to drive the growth of this market. This study also provides a detailed overview of the opportunities along with the current trends observed in the Psoriasis treatment market.
A quantitative analysis of the industry is compiled for a period of 10 years in order to assist players to grow in the market. Insights on specific revenue figures generated are also given in the report, along with projected revenue at the end of the forecast period.
Companies and Manufacturers Covered
The study covers key players operating in the market along with prime schemes and strategies implemented by each player to hold high positions in the industry. Such a tough vendor landscape provides a competitive outlook of the industry, consequently existing as a key insight. These insights were thoroughly analysed and prime business strategies and products that offer high revenue generation capacities were identified. Key players of the global Psoriasis treatment market are included as given below:
Psoriasis treatment Market Key Players
- Johnson & Johnson Services, Inc. (U.S.)
- Pfizer Inc. (U.S.)
- AbbVie Inc. (U.S.)
- Novartis AG (Switzerland)
- LEO Pharma A/S (Denmark)
- Merck & Co., Inc. (U.S.)
- UCB S.A. (Belgium)
- Sun Pharmaceutical Industries Ltd. (India)
- Amgen Inc. (U.S.)
- Eli Lilly and Company (U.S.)
- Evelo Biosciences, Inc. (U.S.)
Market Segments
By Drug Class
- Interleukins
- TNF Inhibitors
- Others
By Treatment Type
- Biologic Drugs
- Small Molecule Systemic Drugs
- Tropical Therapies
By Type
- Psoriatic Arthritis
- Plaque Psoriasis
- Others
By Route of Administration
- Oral
- Parenteral
- Topical
By Distribution Channel
- Hospital Pharmacies
- Online pharmacies
- Retail Pharmacies
By Geography
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- France
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Malaysia
- Philippines
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
Report Objectives
- To define, describe, and forecast the global psoriasis treatment market based on product, and region
- To provide detailed information regarding the major factors influencing the growth of the market (drivers, opportunities, and industry-specific challenges)
- To strategically analyze micromarkets1 with respect to individual growth trends, future prospects, and contributions to the total market
- To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of market segments with respect to four main regions—North America, Europe, Asia Pacific and the Rest of the World (RoW)2
- To strategically profile key players and comprehensively analyze their product portfolios, market shares, and core competencies3
- To track and analyze competitive developments such as acquisitions, expansions, new product launches, and partnerships in the psoriasis treatment market
Table of Content
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Psoriasis Treatment Market
5.1. COVID-19 Landscape: Psoriasis Treatment Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Psoriasis Treatment Market, By Drug Class
8.1. Psoriasis Treatment Market, by Drug Class, 2022-2030
8.1.1. Interleukins
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. TNF Inhibitors
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Others
8.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Psoriasis Treatment Market, By Treatment Type
9.1. Psoriasis Treatment Market, by Treatment Type, 2022-2030
9.1.1. Biologic Drugs
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Small Molecule Systemic Drugs
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Tropical Therapies
9.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Psoriasis Treatment Market, By Type
10.1. Psoriasis Treatment Market, by Type, 2022-2030
10.1.1. Psoriatic Arthritis
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Plaque Psoriasis
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Others
10.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Psoriasis Treatment Market, By Route of Administration
11.1. Psoriasis Treatment Market, by Route of Administration, 2022-2030
11.1.1. Oral
11.1.1.1. Market Revenue and Forecast (2017-2030)
11.1.2. Parenteral
11.1.2.1. Market Revenue and Forecast (2017-2030)
11.1.3. Topical
11.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 12. Global Psoriasis Treatment Market, By Distribution Channel
12.1. Psoriasis Treatment Market, by Distribution Channel, 2022-2030
12.1.1. Hospital Pharmacies
12.1.1.1. Market Revenue and Forecast (2017-2030)
12.1.2. Online pharmacies
12.1.2.1. Market Revenue and Forecast (2017-2030)
12.1.3. Retail Pharmacies
12.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 13. Global Psoriasis Treatment Market, Regional Estimates and Trend Forecast
13.1. North America
13.1.1. Market Revenue and Forecast, by Drug Class (2017-2030)
13.1.2. Market Revenue and Forecast, by Treatment Type (2017-2030)
13.1.3. Market Revenue and Forecast, by Type (2017-2030)
13.1.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.1.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.1.6. U.S.
13.1.6.1. Market Revenue and Forecast, by Drug Class (2017-2030)
13.1.6.2. Market Revenue and Forecast, by Treatment Type (2017-2030)
13.1.6.3. Market Revenue and Forecast, by Type (2017-2030)
13.1.6.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.1.6.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.1.7. Rest of North America
13.1.7.1. Market Revenue and Forecast, by Drug Class (2017-2030)
13.1.7.2. Market Revenue and Forecast, by Treatment Type (2017-2030)
13.1.7.3. Market Revenue and Forecast, by Type (2017-2030)
13.1.7.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.1.7.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.2. Europe
13.2.1. Market Revenue and Forecast, by Drug Class (2017-2030)
13.2.2. Market Revenue and Forecast, by Treatment Type (2017-2030)
13.2.3. Market Revenue and Forecast, by Type (2017-2030)
13.2.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.2.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.2.6. UK
13.2.6.1. Market Revenue and Forecast, by Drug Class (2017-2030)
13.2.6.2. Market Revenue and Forecast, by Treatment Type (2017-2030)
13.2.6.3. Market Revenue and Forecast, by Type (2017-2030)
13.2.6.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.2.6.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.2.7. Germany
13.2.7.1. Market Revenue and Forecast, by Drug Class (2017-2030)
13.2.7.2. Market Revenue and Forecast, by Treatment Type (2017-2030)
13.2.7.3. Market Revenue and Forecast, by Type (2017-2030)
13.2.7.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.2.7.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.2.8. France
13.2.8.1. Market Revenue and Forecast, by Drug Class (2017-2030)
13.2.8.2. Market Revenue and Forecast, by Treatment Type (2017-2030)
13.2.8.3. Market Revenue and Forecast, by Type (2017-2030)
13.2.8.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.2.8.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.2.9. Rest of Europe
13.2.9.1. Market Revenue and Forecast, by Drug Class (2017-2030)
13.2.9.2. Market Revenue and Forecast, by Treatment Type (2017-2030)
13.2.9.3. Market Revenue and Forecast, by Type (2017-2030)
13.2.9.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.2.9.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.3. APAC
13.3.1. Market Revenue and Forecast, by Drug Class (2017-2030)
13.3.2. Market Revenue and Forecast, by Treatment Type (2017-2030)
13.3.3. Market Revenue and Forecast, by Type (2017-2030)
13.3.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.3.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.3.6. India
13.3.6.1. Market Revenue and Forecast, by Drug Class (2017-2030)
13.3.6.2. Market Revenue and Forecast, by Treatment Type (2017-2030)
13.3.6.3. Market Revenue and Forecast, by Type (2017-2030)
13.3.6.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.3.6.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.3.7. China
13.3.7.1. Market Revenue and Forecast, by Drug Class (2017-2030)
13.3.7.2. Market Revenue and Forecast, by Treatment Type (2017-2030)
13.3.7.3. Market Revenue and Forecast, by Type (2017-2030)
13.3.7.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.3.7.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.3.8. Japan
13.3.8.1. Market Revenue and Forecast, by Drug Class (2017-2030)
13.3.8.2. Market Revenue and Forecast, by Treatment Type (2017-2030)
13.3.8.3. Market Revenue and Forecast, by Type (2017-2030)
13.3.8.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.3.8.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.3.9. Rest of APAC
13.3.9.1. Market Revenue and Forecast, by Drug Class (2017-2030)
13.3.9.2. Market Revenue and Forecast, by Treatment Type (2017-2030)
13.3.9.3. Market Revenue and Forecast, by Type (2017-2030)
13.3.9.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.3.9.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.4. MEA
13.4.1. Market Revenue and Forecast, by Drug Class (2017-2030)
13.4.2. Market Revenue and Forecast, by Treatment Type (2017-2030)
13.4.3. Market Revenue and Forecast, by Type (2017-2030)
13.4.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.4.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.4.6. GCC
13.4.6.1. Market Revenue and Forecast, by Drug Class (2017-2030)
13.4.6.2. Market Revenue and Forecast, by Treatment Type (2017-2030)
13.4.6.3. Market Revenue and Forecast, by Type (2017-2030)
13.4.6.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.4.6.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.4.7. North Africa
13.4.7.1. Market Revenue and Forecast, by Drug Class (2017-2030)
13.4.7.2. Market Revenue and Forecast, by Treatment Type (2017-2030)
13.4.7.3. Market Revenue and Forecast, by Type (2017-2030)
13.4.7.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.4.7.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.4.8. South Africa
13.4.8.1. Market Revenue and Forecast, by Drug Class (2017-2030)
13.4.8.2. Market Revenue and Forecast, by Treatment Type (2017-2030)
13.4.8.3. Market Revenue and Forecast, by Type (2017-2030)
13.4.8.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.4.8.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.4.9. Rest of MEA
13.4.9.1. Market Revenue and Forecast, by Drug Class (2017-2030)
13.4.9.2. Market Revenue and Forecast, by Treatment Type (2017-2030)
13.4.9.3. Market Revenue and Forecast, by Type (2017-2030)
13.4.9.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.4.9.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.5. Latin America
13.5.1. Market Revenue and Forecast, by Drug Class (2017-2030)
13.5.2. Market Revenue and Forecast, by Treatment Type (2017-2030)
13.5.3. Market Revenue and Forecast, by Type (2017-2030)
13.5.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.5.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.5.6. Brazil
13.5.6.1. Market Revenue and Forecast, by Drug Class (2017-2030)
13.5.6.2. Market Revenue and Forecast, by Treatment Type (2017-2030)
13.5.6.3. Market Revenue and Forecast, by Type (2017-2030)
13.5.6.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.5.6.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.5.7. Rest of LATAM
13.5.7.1. Market Revenue and Forecast, by Drug Class (2017-2030)
13.5.7.2. Market Revenue and Forecast, by Treatment Type (2017-2030)
13.5.7.3. Market Revenue and Forecast, by Type (2017-2030)
13.5.7.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.5.7.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
Chapter 14. Company Profiles
14.1. Johnson & Johnson Services, Inc. (U.S.)
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. Pfizer Inc. (U.S.)
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. AbbVie Inc. (U.S.)
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. Novartis AG (Switzerland)
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. LEO Pharma A/S (Denmark)
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. Merck & Co., Inc. (U.S.)
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. UCB S.A. (Belgium)
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. Sun Pharmaceutical Industries Ltd. (India)
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. Amgen Inc. (U.S.)
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. Eli Lilly and Company (U.S.)
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
Chapter 15. Research Methodology
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
Chapter 16. Appendix
16.1. About Us
16.2. Glossary of Terms
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 774 402 616
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com
Blog: https://www.pharma-geek.com
0 Comments